SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · IEX Real-Time Price · USD
2.840
-0.010 (-0.35%)
At close: Jul 19, 2024, 4:00 PM
2.880
+0.040 (1.41%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
SAB Biotherapeutics Revenue
SAB Biotherapeutics had revenue of $2.60M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $944.58K with 62.55% year-over-year growth. In the year 2023, SAB Biotherapeutics had annual revenue of $2.24M.
Revenue (ttm)
$2.60M
Revenue Growth
-79.48%
P/S Ratio
10.07
Revenue / Employee
$45,657
Employees
57
Market Cap
26.21M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.24M | -21.67M | -90.63% |
Dec 31, 2022 | 23.90M | -36.97M | -60.73% |
Dec 31, 2021 | 60.88M | 5.64M | 10.21% |
Dec 31, 2020 | 55.24M | 51.80M | 1,504.91% |
Dec 31, 2019 | 3.44M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSABS News
- 4 weeks ago - SAb Biotherapeutics Rebrands as SAB BIO - GlobeNewsWire
- 4 weeks ago - SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions - GlobeNewsWire
- 7 weeks ago - SAB Biotherapeutics Announces Departure of Chief Financial Officer - GlobeNewsWire
- 2 months ago - FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics - GlobeNewsWire
- 2 months ago - SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates - GlobeNewsWire
- 2 months ago - SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors - GlobeNewsWire
- 3 months ago - SAB Biotherapeutics Provides SAB-142 Trial Update - GlobeNewsWire
- 3 months ago - SAB Biotherapeutics to Present at INNODIA Annual Meeting - GlobeNewsWire